Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 864952 | ISIN: US8636671013 | Ticker-Symbol: SYK
Tradegate
21.11.24
09:45 Uhr
366,10 Euro
+0,10
+0,03 %
Branche
Biotechnologie
Aktienmarkt
S&P 500
1-Jahres-Chart
STRYKER CORPORATION Chart 1 Jahr
5-Tage-Chart
STRYKER CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
364,60365,9010:01
364,60366,0010:01
PR Newswire
219 Leser
Artikel bewerten:
(1)

Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment

Finanznachrichten News

PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals.

SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment.SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment.SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment.

Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 cases of severe maternal morbidity occurring each year.2 Notably, 70% of pregnancy-related deaths due to hemorrhage are preventable.3 Stryker's Triton software includes AI technology that can differentiate blood from other fluids and a Bluetooth scale that batch weighs blood-soaked items to help assess blood loss. This provides hospital staff with real-time information to help coordinate the clinical team's hemorrhage response and make informed patient care decisions.

Surgical sponges continue to be the number one retained surgical item with 88% of retained surgical items occurring with a false correct count.4 For nurses trying to locate a missing sponge in the operating room (OR), that can take up to 10 minutes on average.5 Stryker's SurgiCount+ software helps address these problems by featuring a wireless reader that counts, tracks and locates surgical sponges in the OR. RFID-tagged sponges enable unique identification, eliminating false-correct duplicate or unknown counts.

"We are committed to helping keep caregivers and patients safe from harm," said Brandon Jominy, vice president and general manager of Stryker's Surgical Technologies business. "Integrating our SurgiCount+ and Triton technologies on one platform will set a new industry standard for quantifying blood loss and continuing to help reduce retained surgical sponges in the OR."

Additionally, recent studies show that nurse burnout is affecting more than half of all U.S. nurses.6 By integrating these two technologies into one solution, it provides additional benefits to hospitals and staff which includes:

  • Helping save time by standardizing clinical protocols for charting
  • Simplifying workflows and aggregating case data with backend data
  • Helping reduce manual data entry errors through real-time EMR integration
  • Tracking and communicating patient information with one seamless workflow

For more information about Stryker's SurgiCount+ integrated with Triton please visit safeor.com/products/surgicount-triton.

About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com.

Media contact
Beth Sizemore
Sr. Director, Strategic Communications
[email protected]

1. Hoyert DL. Maternal mortality rates in the United States, 2021. NCHS Health E-Stats. 2023. DOI: https://dx.doi.org/10.15620/cdc:124678

2. Callaghan, W.M., Creanga, A.A. and Kuklina, E.V. (2012) "Severe maternal morbidity among delivery and postpartum hospitalizations in the United States," Obstetrics & Gynecology,120(5), pp. 1029-1036. doi:10.1097/aog.0b013e31826d60c5.

3. Building U.S. Capacity to Review and Prevent Maternal Deaths. (2018). Report from nine maternal mortality review committees. https://www.cdcfoundation.org/sites/default/files/files/ReportfromNineMMRCs.pdf

4. Gawande, A. A., Studdert, D. M., Orav, E. J., Brennan, T. A., & Zinner, M. J. (2003). Risk factors for retained instruments and sponges after surgery. The New England Journal of Medicine, 348(3), 229-235. https://doi.org/10.1056/NEJMsa021721

5. Double-blinded survey of 154 Operating Room Nurses from 154 different facilities across the United States. Data on file internally. Conducted August 2020.

6. Rotenstein, L.S., Brown, R., Sinsky, C. et al. The Association of Work Overload with Burnout and Intent to Leave the Job Across the Healthcare Workforce During COVID-19. J GEN INTERN MED 38, 1920-1927 (2023). https://doi.org/10.1007/s11606-023-08153-z

SOURCE Stryker

© 2024 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.